{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360021393548768768.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.clinthera.2020.07.014"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0149291820303489?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0149291820303489?httpAccept=text/plain"}}],"dc:title":[{"@value":"Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380021393548768768","@type":"Researcher","foaf:name":[{"@value":"Ann-Charlott Salabarria"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021393548768769","@type":"Researcher","foaf:name":[{"@value":"Tiffany Luong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021393548768770","@type":"Researcher","foaf:name":[{"@value":"Dwayne R. Roach"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01492918"}],"prism:publicationName":[{"@value":"Clinical Therapeutics"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2020-09","prism:volume":"42","prism:number":"9","prism:startingPage":"1659","prism:endingPage":"1680"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0149291820303489?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0149291820303489?httpAccept=text/plain"}],"createdAt":"2020-08-31","modifiedAt":"2025-09-27","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050866448316201088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Plasticity of bone marrow-derived cell differentiation depending on microenvironments in the skin"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905636659072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Phagemid-based capsid system for CRISPR-Cas13a antimicrobials targeting methicillin-resistant Staphylococcus aureus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588381082205568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.clinthera.2020.07.014"},{"@type":"CROSSREF","@value":"10.1038/s42003-024-06754-w_references_DOI_KvuHF0sLZYK9fISJpkZFgGEGkWS"},{"@type":"CROSSREF","@value":"10.3389/fphys.2024.1391640_references_DOI_KvuHF0sLZYK9fISJpkZFgGEGkWS"},{"@type":"CROSSREF","@value":"10.3390/microorganisms12101986_references_DOI_KvuHF0sLZYK9fISJpkZFgGEGkWS"}]}